Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769181 | 0.84 | LRRK2 (0.52) | LRRK2BRD4TLR8TLR7 | |
| SCHEMBL381679 | 0.84 | LRRK2 (0.51) | BTKLRRK2 | |
| SCHEMBL3768924 | 0.80 | LRRK2 (0.48) | BTKLRRK2 | |
| SCHEMBL3715167 | 0.80 | NOS1 (0.52) | LRRK2NOS1NOS2NOS3 | |
| SCHEMBL3780521 | 0.78 | LRRK2 (0.53) | BTKLRRK2BRD4ATAD2 | |
| SCHEMBL3774010 | 0.78 | TLR8 (0.53) | LRRK2BRD4ATAD2TLR8TLR7 | |
| SCHEMBL3766197 | 0.77 | LRRK2 (0.61) | LRRK2 | |
| SCHEMBL3775093 | 0.75 | LRRK2 (0.63) | LRRK2 | |
| SCHEMBL3769161 | 0.75 | LRRK2 (0.63) | LRRK2 | |
| SCHEMBL3771723 | 0.74 | LRRK2 (0.54) | BTKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | BTK 939/4885LRRK2 2309/4885BRD4 347/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | BTK 928/4885LRRK2 2208/4885BRD4 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.